Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin for early diabetic nephropathy
ChiCTR-IPR-17014233Phase 4Recruiting
- Sponsor
- Zhu Xianyi Memorial Hospital
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of saxagliptin in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Zhu Xianyi Memorial Hospital. Primary endpoints: Albumin-to-creatinine ratio and Stromal cell-derived factor 1 alpha. Started Dec 2017; status: recruiting.
02
Drugs
saxagliptin
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-IPR-17014233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17014233.